Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Dental Pain, Surgery, Dental
Interventions: GW406381; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Generalized Anxiety Disorder
Interventions: Quetiapine fumarate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 58
States / cities: Springdale, Arizona • Little Rock, Arkansas • Encino, California + 55 more

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • St. Petersburg, Florida • Brooklyn, New York + 1 more

Conditions: Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
Interventions: AAV2-hRPE65v2,voretigene neparvovec-rzyl; Biological
Lead sponsor: Spark Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 2
States / cities: Iowa City, Iowa • Philadelphia, Pennsylvania

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab, Sham Control; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 65 more

Conditions: Dose Finding Study
Interventions: TAK-058 (ENV8058), Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: COVID-19 Pneumonia
Interventions: MSTT1041A, MSTT1041A-matched Placebo, UTTR1147A, UTTR1147A-matched Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 24
States / cities: Little Rock, Arkansas • Chula Vista, California • La Mesa, California + 20 more

Conditions: Primary Hyperoxaluria Type 1 (PH1)
Interventions: Placebo, Lumasiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
Interventions: Memantine Hydrochloride (HCl), Placebo capsules; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 64
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Cataract
Interventions: Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL, Control Monofocal Intraocular Lens: TECNIS Monofocal IOL; Device
Lead sponsor: Johnson & Johnson Surgical Vision, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 247 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 10
States / cities: Torrance, California • Bradenton, Florida • Jacksonville, Florida + 6 more

Conditions: Menstruation Disorders
Interventions: Anastrozole; Drug
Lead sponsor: Meditrina Pharmaceuticals; Industry
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 2
States / cities: Kalamazoo, Michigan • Southfield, Michigan

Conditions: Early Alzheimers Disease
Interventions: buntanetap/posiphen, Placebo; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 78
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more

Conditions: Tobacco Smoking
Interventions: Genetic Education Session, Nutrition Education Session; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 103 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Skin Laxity, Wrinkle, Brow Lifting
Interventions: Sofwave Treatments; Device
Lead sponsor: Sofwave Medical LTD; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Sacramento, California • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Crohn's Disease
Interventions: natalizumab; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 18
States / cities: Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 14 more

Conditions: Spinal Cord Injuries, Neurogenic Bladder
Interventions: Lactobacillus RhamnosusGG, Saline bladder wash; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Influenza
Interventions: Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4); Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 1,350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 10
States / cities: Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more

Conditions: Major Depressive Disorder
Interventions: Brainsway Deep TMS System; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Tuscaloosa, Alabama • Redlands, California • Palm Beach, Florida + 4 more

Conditions: Pneumococcal Vaccines
Interventions: 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 45
States / cities: Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more

Conditions: Alzheimer's Disease
Interventions: AC-3933, Sugar Pill; Drug · Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: LIttle Rock, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Dry Eye Disease
Interventions: Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Shelby, North Carolina

Conditions: Severe Hypertriglyceridemia
Interventions: ARO-APOC3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 33
States / cities: Beverly Hills, California • Palm Springs, California • Boca Raton, Florida + 26 more

Conditions: Prurigo Nodularis (PN)
Interventions: ICP-322, Placebo; Drug
Lead sponsor: Beijing InnoCare Pharma Tech Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fremont, California + 11 more

Search by objective public record fields.

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Dental Pain (Following Third Molar Tooth Extraction) Study

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants

A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine

Clinical Investigation of the Next Generation Intraocular Lens

Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

Developing Genetic Education for Smoking Cessation

Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Intravesical LGG VS Saline Bladder Wash RCT

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis